Zostavax (varicella zoster virus) vaccine ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01506661 (ClinicalTrials.gov) | January 2012 | 5/1/2012 | Safety of Zostavax Vaccination in Rheumatoid Arthritis | Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis;Varicella Zoster | Drug: Zostavax (varicella zoster virus) vaccine | Oklahoma Medical Research Foundation | NULL | Completed | 50 Years | 80 Years | All | 20 | Phase 1 | United States |